An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)
Latest Information Update: 13 Oct 2022
At a glance
- Drugs Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
- Indications Early breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 07 Jul 2021 Status changed from active, no longer recruiting to completed.
- 06 Apr 2021 Planned End Date changed from 28 Dec 2020 to 11 Jun 2021.
- 06 Apr 2021 Planned primary completion date changed from 28 Dec 2020 to 11 Jun 2021.